Tag: THROMBOLEX

 Thrombolex, Inc., a medical device company focused on developing innovative products for the treatment of arterial and venous thromboembolic diseases, announced never-before-reported major reductions in obstruction in all of the segmental pulmonary arteries (PA), based on independent core lab data analysis of 107 patients from 18 sites in the USA, with acute intermediate-risk pulmonary embolism (PE), using the BASHIR™ Endovascular Catheter and small doses of tPA. The NIH sponsored RESCUE trial also showed unsurpassed efficacy and safety in this patient population compared to recently published studies with other FDA- cleared devices These new data have just been published.in the Journal ... Read more

 THROMBOLEX, Inc. will be attending the VEINS Conference (Booth T8) and VIVA Physicians Conference (Booth #502) in Las Vegas, NV October 3-7. There will be live demonstrations and meetings with the Executive Team about the family of BASHIR™ Endovascular Catheters. The BASHIR™ Endovascular Catheter and the BASHIR™ Plus Endovascular Catheters are intended for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. They are also now intended for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature, enabling the restoration of blood flow in patients with venous thrombus. To continue ... Read more